Boehringer Ingelheim and Palatin Technologies Announce Collaboration Revenue
What happened
The collaboration between Boehringer Ingelheim and Palatin Technologies resulted in $13.2 million in revenue for the fiscal year ended June 30, 2026. This revenue included $9.4 million related to Boehringer Ingelheim, while $3.8 million was received as non-cash license revenue under the Altanispac Labs agreement. Palatin Technologies stated it had $7.5 million in cash and cash equivalents as of June 30, 2026, and required additional funding to continue operations.
From prnewswire.com
Why it matters
The partnership focuses on rare obesity disorders linked to the melanocortin 4 receptor (MC4R) pathway. Future studies are planned to assess potential treatments, including a Phase 1 SAD/MAD study for an injectable agonist targeted to begin in the first half of calendar year 2027.
From prnewswire.com
Who's involved
- Boehringer IngelheimGerman pharmaceutical company involved in the collaboration and targeted by the revenue.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Boehringer IngelheimSpeculative
Boehringer Ingelheim might see a segment of its business revenue from the collaboration.